Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use
US11655216B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 9, 2017 |
| Grant date | May 23, 2023 |
| Priority date | — |
| Expiry date | Oct 9, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/08
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
In its many embodiments, the present invention provides certain substituted aryl and heteroaryl ether compounds of the Formula (I): and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, L, R4, L1, Q, and R5 are as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-β receptor (LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.